Allakos Appoints Chin Lee, MD, MPH, as Chief Medical Officer

Allakos, a clinical stage biotechnology company focused on developing novel therapeutics for allergy, inflammatory and proliferative diseases, named Dr. Lee as Chief Medical Officer. Dr. Lee has over 20 years of clinical research and development experience in the biopharmaceutical industry and academia across multiple therapeutic areas, including rheumatology, dermatology, allergy & asthma, and gastroenterology, focused on the development of small molecules and biologic therapies for immune mediated conditions. Prior to Allakos, Dr. Lee served as the Chief Medical Officer at Connect Biopharma, a clinical-stage company focused on the development of innovative therapies for chronic inflammatory diseases based on T cell-driven research. Dr. Lee also previously served as Vice President, Head of Clinical Science, and Chief Medical Officer at Theravance Biopharma, Inc, Lead Group Medical Director within the Genentech Research & Early Development (gRED) group, and held roles of increasing responsibility within the Immunology Therapeutic Area at Eli Lilly & Co., and the Immunoscience Group at Abbott (now Abbvie). During his time in industry, Dr. Lee has successfully led the submission of global regulatory filings and participated in product commercialization across multiple autoimmune and immunology disease indications.

Prior to entering the biopharmaceutical industry, Dr. Lee was on the academic faculty at the Northwestern University Feinberg School of Medicine in the Division of Rheumatology. Dr. Lee received his BS in Biology and an MD from the University of North Carolina at Chapel Hill, and an MPH from Northwestern University.